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Abstract
Background: Peach is a common elicitor of food allergic reactions. Peach‐induced
immediate reactions may occur as benign pollen‐food syndromes, usually due to
birch pollen‐related PR‐10 cross‐reactivity in temperate climates, and as potentially
severe primary food allergies, predominantly related to nsLTP Pru p 3 in Mediter-
ranean regions. The newly described peach allergen Pru p 7 has gained recent atten-
tion as a potential peach allergy severity marker. Sensitization to Pru p 7 and its
allergenic homologues of the gibberellin‐regulated protein family occurs in areas
with high Cupressaceae tree pollen exposure.
Objective: We sought to investigate the distribution, clinical characteristics and
molecular associations of Pru p 7 sensitization among subjects with suspected peach
allergy in different regions of France.
Methods: Subjects with suspected peach allergy (n = 316) were included. Diagnostic
work‐up was performed according to current guidelines, including open food chal-
lenge when required. IgE antibody measurements and competition experiments were
performed using the ImmunoCAP assay platform.
Results: Sensitization to Pru p 7 was present in 171 (54%) of all subjects in the
study and in 123 of 198 (62%) diagnosed as peach allergic, more than half of whom
were sensitized to no other peach allergen. Frequency and magnitude of Pru p 7
sensitization were associated with the presence of peach allergy, the clinical severity
of peach‐induced allergic reactions and the level of cypress pollen exposure. Cypress
pollen extract completely outcompeted IgE binding to Pru p 7. Pru p 7 was extre-
mely potent in basophil activation tests.
Conclusion and Clinical Relevance: A subtype of Cupressaceae pollinosis, character-
ized by Pru p 7 sensitization, can be an underlying cause of severe peach allergy.
K E YWORD S
allergens and epitopes, anaphylaxis, basophil, cypress pollinosis, food allergy, IgE, immunological
tests, peamaclein, Pru p 7
1 | INTRODUCTION
Fruit and vegetables account for the most common aetiology of food
allergies in teenagers and adults.1-4 Severe reactions are frequent,
with fruit and vegetables reported as causative in 5% of all cases of
food anaphylaxis in children and adolescents in a range of European
countries,5 and confirmed as culprit in 7% of children seeking
emergency care at a major Madrid hospital for anaphylaxis‐like
symptoms.6 Peach‐induced immediate reactions are frequent in pol-
len‐allergic patients and often occur as pollen‐food syndromes
(PFS).7-9 Birch pollen‐related PR‐10 sensitization underlies most
cases of peach‐induced oral allergy syndrome (OAS) occurring in
temperate climates, while sensitization to non‐specific lipid transfer
proteins (nsLTPs) is predominant in Mediterranean regions and may
induce OAS as well as severe reactions.1,4,9-11 In southern Europe,
primary food allergies, including peach allergy (PA), may account for
up to 96% of food allergy cases.1 Sensitization to nsLTPs, either as
primary food allergy or as PFS, accounts for most of PA cases in the
Mediterranean region.1,12,13 However, some PA patients have been
found to lack sensitization to Pru p 1 (PR‐10), Pru p 3 (nsLTP) and
Pru p 4 (profilin), despite a convincing clinical history and a strongly
positive skin test with fresh peach.14-16 Pru p 7, also referred to as
peamaclein, a member of the gibberellin‐regulated protein (GRP)
family, was described as a novel peach allergen.14 We have previ-
ously reported Pru p 7 as a major allergen associated with severe
clinical symptoms and strong cypress pollen (CP) sensitization in PA
patients from Marseille, southern France.16 As France comprises a
wide spectrum of geographic and climatic conditions, including conti-
nental, oceanic, Mediterranean and alpine regions, a variety of pollen
sensitizations may occur across the country, making a fuller under-
standing of different pollen‐related food allergies particularly rele-
vant. In this study, we set out to further characterize the
implications of Pru p 7 sensitization in PA in Mediterranean and
non‐Mediterranean regions of France.
2 | METHODS
2.1 | Patients
Three hundred sixteen outpatients residing in southern France (42nd to
46th latitude north), seeking allergy work‐up for a suspicion of peach‐
induced food allergy symptoms, were included in this study. Clinical
data were collected by means of a standardized questionnaire retro-
spectively completed by the allergists. Continental, oceanic and
Mediterranean climates were represented. Five geographic regions
were defined based on cypress and birch pollen counts17 and numbered
1‐5 according to ascending order of cypress/birch pollen count ratio:
region 1 (Lyon and continental environments), region 2 (Bordeaux and
neighbouring Atlantic coastal regions), region 3 (alpine and continental
regions including Toulouse and southern Alps), region 4 (Nice and
Montpellier regions) and region 5 (Marseille and Var regions, southern-
most Mediterranean environments) (Table 1). Each participant's area of
residency was categorized as belonging to one of these regions.
2.2 | Diagnostic criteria and procedures
Diagnosis of PA was confirmed or rejected according to ICON and
EAACI guidelines for food allergy.18-20 The combination of a convincing
clinical history of immediate reaction to peach in the past year, positive
skin prick tests (SPT) to peach extract (Stallergènes‐Greer, ALK‐Abelló)
or fresh peach defined as a weal >50% of the positive control, and/or
IgE sensitization to peach, formed the basis of a PA diagnosis.20 Con-
vincing clinical history was defined as one or more immediate reaction
(s) within 2 hours after peach ingestion, inhalation or direct contact,
presenting as acute urticaria or angioedema, contact urticaria, OAS,
food‐dependent exercise‐induced anaphylaxis, laryngeal swelling, imme-
diate vomiting, rhinitis, cough, wheezing, bronchospasm, hypotension
or loss of consciousness. The use of peach‐specific IgE determination in
conjunction with clinical history and peach SPT helped reduce the need
for oral food challenge (OFC) as advised.21 Diagnostic OFC was per-
formed according to ICON and EAACI guidelines 18,20 and previous PA
studies 3,11 if negative SPT and IgE results were discordant with clinical
history. Patients who had had a life‐threatening reaction to peach dur-
ing the last 12 months did not undergo OFC, in line with current guide-
lines.18 A total of 61 patients were subjected to OFC, of whom 41
failed (PA) and 20 passed (peach tolerant, PT).
OFC followed an open protocol, with peach peel and pulp tested
separately. After a negative labial challenge test, doses of fresh
peach were administered in sequential 20‐minute steps, starting
the provocation with 1/128 of one fruit (approximately 1 g), then
proceeding with 1/64, 1/32, 1/16, 1/8, 1/4 and 1/2 (highest dose
approximately 65 g). The OFC was stopped if objective or severe
symptoms appeared: erythema, urticaria, sneezing, wheezing, cough,
vomiting, severe abdominal pain, hypotension, neurological symp-
toms or difficulty to breathe. Patients were kept in day‐care units at
close proximity of an intensive care unit during the challenge proce-
dure and were monitored for 4 hours after ingestion of the last dose
of peach. At the end of the diagnostic procedure, patients were cat-
egorized as PA or PT.
The diagnostic investigation for other food allergies followed the
same steps as that for PA.
2.3 | Assessment of clinical severity
The severity of clinical reactions was graded following the recently
proposed classification of food allergic and anaphylactic reac-
tions22,23: grade 1 comprising local reactions without systemic
involvement: redness, swelling and itching; grade 2 mild to moderate
systemic reactions involving distant skin locations, upper airways
and/or gastrointestinal symptoms, but without cardiovascular or res-
piratory involvement: urticaria, angioedema, flush and gastrointesti-
nal symptoms; grade 3 severe systemic reactions with cardiovascular
and/or bronchial and laryngeal involvement: wheezing, stridor, objec-
tive dyspnoea, tachycardia, lowered blood pressure and shock.
2.4 | Ethics statement
Determination of IgE to whole allergen extracts and molecular aller-
gens was part of routine investigations. Patients received written labo-
ratory reports and the study was based on a retrospective review of
medical records and laboratory results. In accordance with the Decla-
ration of Helsinki and the French law on research involving humans,
ethics committee approval and patient consent were not required for
this type of non‐interventional study, provided the patients received
information and retained the right to oppose to the use of excess
serum and anonymized medical data for research purposes.24,25
2.5 | IgE antibody measurements
IgE antibodies directed to natural extracts and molecular allergens
were measured with the ImmunoCAP™ assay platform (Thermo Fisher
Scientific, Uppsala, Sweden) during the routine diagnostic procedure.
All sera were assayed for IgE to peach, CP, PR‐10 protein rPru p 1,
nsLTP rPru p 3, profilin rPru p 4, the major and specific CP allergen
pectate lyase nCup a 1, and MUXF3, representing cross‐reactive car-
bohydrate determinants (CCD). IgE assays to additional allergen
extracts and components were performed according to each patient's
history. IgE to natural and recombinant Pru p 7 was measured on
excess serum with experimental ImmunoCAP™ tests. rPru p 1 and rPru
p 4 were taken as surrogates for their respective allergen families due
to high level of molecular similarity and cross‐reactivity.2,26 Pru p 3,
the immunodominant nsLTP and a possible primary sensitizer for this
allergen family,12,27 was considered representative of nsLTP sensitiza-
tion. Specific IgE values exceeding the assay's stated limit of quantita-
tion of 0.10 kUA/L were considered positive.
28 For comparison of the
experimental ImmunoCAP assay to an independent method for detec-
tion of IgE to nPru p 7, a subset of sera were analysed with the multi-
plexed FABER® assay (CAAM, Rome, Italy).29,30
2.6 | Preparation of natural and recombinant peach
allergens and experimental ImmunoCAP™ tests
Natural Pru p 7 was purified from extract of canned peaches by
sequential steps of cation exchange, size exclusion and reversed
phase chromatography. Bioaffinity adsorption was then performed
to eliminate any residual amount of LTPs. Natural Pru p 3 was puri-
fied from peach peel extract by affinity chromatography using a
monoclonal anti‐Pru p 3 antibody, followed by cation exchange chro-
matography. Recombinant Pru p 7 and Pru p 3 were expressed in
Pichia pastoris and purified from culture medium by cation exchange
or metal ion affinity chromatography, followed by size exclusion or
cation exchange chromatography. Purity, homogeneity and identity
of the allergen preparations were verified by SDS‐PAGE, analytical
size exclusion chromatography, mass spectrometry and immunologi-
cal activity using ImmunoCAP™ and serum samples with defined IgE
reactivities. All chromatography media and equipment were obtained
from GE Healthcare Life Sciences (Uppsala, Sweden). Experimental
ImmunoCAP™ tests were prepared as described.31
2.7 | IgE competition experiments
Cross‐reactivity between Pru p 7 and CP was studied by preincubat-
ing serum samples for 2 hours at room temperature either with CP
extract (15% w/v final concentration, 42 sera) or with rPru p 7
(100 μg/mL final concentration, 33 sera) prior to measurement of IgE
binding to rPru p 7 or CP ImmunoCAP solid phase, respectively.
Percent inhibition was calculated as reduction of IgE binding in
comparison with serum samples pre‐incubated with buffer alone.
Dose‐dependent inhibition was performed with four samples. Two
samples were incubated with 15% (w/v) CP extract and a 4‐fold dilu-
tion series thereof, followed by measurement of IgE binding to Pru p
7. Two other samples were instead pre‐incubated with rPru p 7 in a
4‐fold dilution series from 200 to 0.2 μg/mL, followed by measure-
ment of IgE binding to CP extract.
2.8 | Basophil activation tests
Basophil activation tests (BAT) were performed with a commercial
CD193 (CCR3)/CD63 kit (Bühlmann Laboratories, Hochbuch,
Switzerland) in a subset of patients. Peach extract, Mal d 1 (PR‐10),
Tri a 12 (profilin), and cow's milk extract (Bühlmann Laboratories)
and recombinant and natural Pru p 7 and Pru p 3 were used as
allergen reagents. Milk extract served as a negative control for foods
regularly consumed and tolerated by each tested patient. Extracts
TABLE 1 Geographic and demographic characteristics of the study population
All regions Region 5 Region 4 Region 3 Region 2 Region 1
Pollen counts (per year and m3)
Birch 639 69 176 226 1077 1648
Cypress 11 408 18 782 17 251 4276 9021 7712
Cypress/birch ratio 18 272 98 19 8 5
All patients 316 205 27 35 28 21
Sex ratio (M/F) 0.7 0.8 0.9 0.5 1.0 0.8
Age (years; median, IQR) 18 (11‐33) 17 (11‐33) 28 (18‐47) 21 (12‐32) 16 (10‐27) 16 (11‐32)
Peach allergic patients
Sample size (number, %) 198 (63%) 133 (65%) 22 (81%) 20 (57%) 13 (46%) 10 (48%)
Sex ratio (M/F) 0.8 0.8 1.0 0.5 1.2 0.8
Age (years; median, IQR) 21 (13‐36) 21 (13‐36) 32 (21‐47) 19 (14‐32) 17 (9‐31) 16 (13‐34)
Peach tolerant patients
Sample size (number, %) 118 (37%) 72 (35%) 5 (19%) 15 (43%) 15 (54%) 11 (52%)
Sex ratio (M/F) 0.7 0.8 0.7 0.4 0.9 0.8
Age (years; median, IQR) 15 (10‐28) 14 (9‐26) 15 (13‐24) 23 (10‐32) 15 (10‐25) 17 (10‐31)
Regions 1‐5 were defined in ascending order of cypress to birch ratio. Outpatients seeking allergy work‐up for a history of peach‐induced symptoms
were included. Peach allergy was confirmed or rejected according to ICON and EAACI guidelines for food allergy.
and molecular allergens obtained from Bühlmann Laboratories were
used at final concentrations of 2.5, 1, 0.5 and 0.05 times the manu-
facturer's recommended concentration, that is 62.5, 25, 12.5 and
1.25 ng/mL for peach and milk extracts, and 625, 250, 125 and
12.5 ng/mL for Mal d 1 and Tri a 12.
Natural and recombinant Pru p 7 was applied at 11 different
concentrations, ranging from 0.25 pg/mL to 2.5 μg/mL. Natural and
recombinant Pru p 3 was applied at final concentrations of 5 ng/
mL, 50 ng/mL and 2.5 μg/mL. Positive and negative controls (patient
background, anti‐FcεRI and formyl‐methionyl‐leucyl‐phenylalanine)
were assayed in duplicate at the start and end of the experiment
for each patient. Analysis was performed with a Canto II flow
cytometer and FACS Diva software (BD Biosciences, Franklin Lakes,
NJ). Five hundred basophils or more were analysed for each activa-
tion condition. Background CD63 expression was lower than 5% in
all patients, and no non‐responder (anti‐FcεRI‐induced CD63
expression of 10% or less) was found. BAT was considered positive
for an allergen concentration if CD63 expression exceeded twice
the highest background result in each patient. EC50, CD‐sens and
the ratio of maximal activation Pru p 7/anti‐FcεRI activation were
calculated as described.32,33
2.9 | Statistical data analysis
Median and IQR for IgE were calculated for sensitized subjects in
each group. GraphPad Prism (version 7, La Jolla, CA), SPSS (version
25, Chicago, IL) and R (version 3.3.2, R Foundation for Statistical
Computing, Vienna, Austria) were used for statistical analyses. Dif-
ferences with a P value < 0.05 were considered statistically signifi-
cant. Binomial variables were compared using Fisher's exact test
and modelled according to multiple binomial logistic regression
models. Ordinal variables (reaction grade and region of residency
according to pollen counts) were compared using the asymptotic
general independence test and modelled according to multiple ordi-
nal regression models. Continuous variables were compared using
Mann‐Whitney's test and modelled according to multiple linear
regression models. Correlation studies were done by calculating
Spearman's correlation coefficient. Odds ratios were calculated as
previously described.34
3 | RESULTS
3.1 | Demographic and food allergy characteristics
of the study population
A total of 316 patients from the southern part of France were ret-
rospectively included in the study, with a median age of 18 years
(range 0.13‐74) and sex (M/F) ratio 0.7. Subjects were classified
according to two diagnostic categories: PA and PT (Table 1). PA
was diagnosed in 198 (63%) patients. Allergy to other fruits (mainly
Rosaceae, Citrus and exotic fruits) was found in 157 (79%) of PA
patients, while allergy to legumes, tree nuts, cereals and seeds was
found in 46 (23%). Among the 118 PT patients, allergy to other
fruits or vegetables was found in 42 (36%) and to legumes, tree
nuts, cereals and seeds in 64 (54%). In 33 (28%) of the PT subjects,
no plant food allergy was found (Figure S1). Involvement of a
cofactor was reported in 24 (12%) of the PA patients, exercise
being the most frequent (n = 19). Among the symptoms experi-
enced, eyelid oedema was reported by 19 (10%) of the PA
patients.
3.2 | Pru p 7 sensitization is present in all regions
and is higher and more common in PA than PT
patients
Overall, Pru p 7 sensitization was found in 171/316 (54%) patients
(Table 2). A gradient of Pru p 7 sensitization from north (region 1,
29% prevalence) to south (region 5, 60% prevalence) was observed,
P = 0.003 (Figure 1). Pru p 7 sensitization was more frequent in PA
(123/198, 62%) than in PT (48/118, 41%) patients, P = 0.0002. It
was positively and independently related to PA (OR [CI95]: 2.5 [1.4‐
4.6]; P = 0.003). Apparent monosensitization to Pru p 7, that is with-
out detectable IgE to any of the other tested peach allergens (Pru p
1, Pru p 3, Pru p 4), was more frequent in PA (66/123, 54%) than in
PT (8/48, 17%) patients, P < 0.0001.
The concentrations of IgE to Pru p 7 were higher in PA than PT
patients sensitized to this allergen (median [IQR]: 3.4 [0.5‐8.3] vs 0.3
[0.2‐0.5] kUA/L; P < 0.0001) (Table 2). Data on sensitization to other
molecular allergens in PA and PT patients are available in Tables S1
and S2.
For comparative purposes, sera of six PA subjects with IgE to
Pru p 7 by ImmunoCAP were also analysed with the FABER® assay
(CAAM, Rome, Italy) and concordant results were obtained in five of
these (83%).
3.3 | Pru p 7 sensitization is associated with the
severity of reaction and cofactor involvement
Figure 2 shows the levels of IgE antibody responses to peach, indi-
vidual peach components, CCD and CP in the PA and PT subjects,
illustrating the prominent difference in Pru p 7 sensitization between
these groups. Further, Pru p 7 sensitization was more frequent in PA
patients who experienced grade 3 reactions (61/78, 78%) than in
those who experienced grade 2 (38/59, 64%) or grade 1 (24/61,
39%) reactions, P < 0.0001 (Figure 3A). Likewise, the severity of
reactions elicited by peach was significantly associated with the con-
centration of IgE to Pru p 7 (Figure 3B). Odds ratio calculation
showed that Pru p 7 sensitization was positively and independently
related to a higher prevalence of grade 3 reactions (OR [CI95]: 3.7
[1.6‐8.5]; P = 0.002), and negatively related to grade 1 (OR [CI95]:
0.2 [0.1‐0.4]; P < 0.0001). This association remained significant after
adjustment for sensitization to other peach allergens and to CP as
potential confounding covariates.
Cofactor involvement was significantly more frequent in Pru p 7‐
sensitized patients (22/171 vs 7/145, P = 0.01), but eyelid oedema
during the allergic reaction was not (15/171 vs 5/145, P = 0.06).
3.4 | Pru p 7 induces basophil activation in PA
patients
The ability of Pru p 7 to activate effector cells was assessed with
BAT (Figure 4). The test was performed with peach extract, natural
and recombinant Pru p 7, available representative molecules for rele-
vant allergen families: nsLTP (Pru p 3), PR‐10 (Mal d 1) and profilin
(Tri a 12), and a tolerance control allergen, that is cow's milk, in 9 PA
patients sensitized to Pru p 7 and in one PT, Pru p 7 non‐sensitized
patient with plant food‐induced anaphylaxis. Comparable results
were obtained with the natural and recombinant Pru p 7 and with
natural and recombinant Pru p 3. All Pru p 7‐sensitized patients dis-
played basophil activation induced by peach extract and Pru p 7 as
monitored by CD63 membrane expression, but no activation with
the other allergens tested, nor with cow's milk extract (Table S3).
The PT patient's basophils were not activated by any of the extracts
or molecular allergens tested (Table S3). Basophil sensitivity to Pru p
7‐induced activation was monitored through EC50, CD‐sens and the
lowest activating concentration. Median EC50 was 0.05 ng/mL (IQR
0.0125‐1.25) and median CD‐sens was 2000 (IQR 80‐8000). EC50
and the lowest activating concentration were lower in PA patients
without cofactor involvement (n = 6) than in those who required a
cofactor for reaction to peach (n = 3), with a similar trend for CD‐
sens (Table 3). The ratio of maximal rPru p 7‐induced activation to
anti‐RFcεI‐induced activation was close to 1 in both groups.
3.5 | IgE to Pru p 7 is associated with and
cross‐reactive to IgE to cypress pollen
We have previously described a ubiquitous co‐sensitization to CP in
Pru p 7 sensitized individuals.16 Among the 171 Pru p 7 sensitized
subjects in the present study, all but one, who had Pru p 7 IgE at
the positivity threshold of the assay (0.10 kUA/L), were also sensi-
tized to CP.
To study more directly a likely cross‐reactivity between Pru p 7
and CP, we performed a dose‐response IgE competition experiment
with sera from four patients sensitized to CP and Pru p 7. Preincu-
bation with different concentrations of CP extract caused a gradually
increasing and ultimately almost complete (98‐99%) inhibition of IgE
binding to Pru p 7 at the final inhibitor concentration of 15% (w/v)
(not shown). In contrast, preincubation with Pru p 7 only partly (67‐
72%) prevented IgE binding to immobilized CP extract even at the
highest inhibitor concentration applied (not shown).
We next performed single‐point inhibition of IgE binding to Pru
p 7 in 42 patients’ sera, with a fixed final concentration of 15% (w/v)
of CP extract. This resulted in >80% inhibition in 38 of the 42 sera
and >60% in the remaining four (Figure 5A). Conversely, single‐point
inhibition of IgE binding to CP extract by Pru p 7, at a fixed final
concentration of 100 μg/mL, was performed in 33 patients’ sera and
resulted in >40% inhibition in only 9/33 (27%) and less than 20% in
10/33 (30%) of the sera tested (Figure 5B). The ability of Pru p 7 to
inhibit IgE binding to CP extract was negatively correlated to the
ratio of IgE to Cup a 1/Pru p 7 (Spearman rho −0.7, CI95 −0.9 to
−0.5, P < 0.0001), reflecting the proportion of CP‐specific IgE direc-
ted to Cup a 1, which is structurally unrelated to Pru p 7.
3.6 | Cypress pollen exposure determines regional
peach molecular sensitization profiles
Using a multivariate model of CP sensitization including all tested
peach allergens as covariates, we found that no peach allergen other
than Pru p 7 was significantly associated with CP sensitization
(Table S4). The relationship between CP and Pru p 7 sensitization
was further assessed by sorting patients by region of residency as
described in Methods (Table 1). Ordinal logistic regression models
illustrated a strong relationship between the cypress/birch pollen
count ratio and the occurrence of sensitization to CP, Pru p 7 or Pru
p 1 (Table S5). This relationship was positive for CP and Pru p 7 sen-
sitization (P < 0.0001 and P = 0.0001, respectively), and inverse for
Pru p 1 sensitization, a surrogate of Bet v 1 sensitization (P = 0.03).
Further multivariate analysis of CP, Pru p 1 and Pru p 7 sensitiza-
tions found independent relationships between these covariates and
cypress/birch pollen count ratios, consisting of a quantitative effect
of CP exposure associated with higher prevalence of Pru p 7
(P = 0.03) and lower prevalence of Pru p 1 sensitization (P = 0.003)
among CP sensitized subjects (Table S5).
4 | DISCUSSION
We report here that Pru p 7 is a major allergen in PA patients from
southern France, in this study showing a prevalence of Pru p 7 sen-
sitization exceeding 60%. In 54% of Pru p 7‐sensitized PA patients,
there was no concomitant sensitization to other available peach
allergens. The occurrence and level of Pru p 7 sensitization were
higher in severe PA with peach‐induced anaphylactic manifestations,
that is grade 3 reactions of the EAACI classification,23 than in PA
patients with lower grade reactions. The functional potency of Pru p
7 was confirmed with BAT. Strong basophil activation was induced
in Pru p 7‐sensitized PA patients, with lowest activating concentra-
tions of Pru p 7 in the range of picograms/millilitre and median EC50
at 0.05 ng/L, while median CD‐sens was 2000, indicating a biological
potency higher than other food allergens.33,35-37
In all but one borderline case in this study, Pru p 7 sensitization
was associated with CP sensitization. The link between CP and Pru
p 7 sensitization was further explored with IgE competition experi-
ments. We found that CP extract could inhibit 80‐100% of IgE bind-
ing to Pru p 7 in 90% of the 42 sera analysed, whereas Pru p 7 only
partly inhibited IgE binding to CP extract. Based on these results and
the association between Pru p 7 sensitization and the intensity of
CP exposure, we believe that CP acts as a primary sensitizer, eliciting
in a proportion of individuals an IgE response that cross‐reacts with
Pru p 7. A partially characterized 14 kDa CP protein called BP14 has
been shown to share a stretch of homology and cross‐reactivity with
snakin‐1 from potato, a protein related to Pru p 7 and other mem-
bers of the GRP protein family.38 In our study, clinical reactions to
potato were reported by only two Pru p 7 sensitized patients, one
of which was additionally sensitized to Pru p 4.
Our data show that Pru p 7 sensitization in PA patients from
southern France belongs to the PFS through its association with CP.
Similar to other examples of PFS, Pru p 7‐induced reactions occur
mainly in adolescents and young adults. However, food allergy symp-
toms are more severe in Pru p 7‐related PFS than in previously
described examples of PFS.
Despite early reports on the association of PA with cypress polli-
nosis,39 the prevalence of cypress‐associated peach sensitization and
PA is currently unknown. In a cohort of 1280 cypress‐sensitized
patients from France, 165 (13%) patients had peach sensitization as
defined by positive prick‐to‐prick tests to peach, and 29 of these
165 (18%) had a history of peach‐induced symptoms.40 In regard to
molecular sensitization relevant to peach allergy in our region,
preliminary data indicate that 15‐25% of cypress pollinosis patients
may be Pru p 7 sensitized (unpublished observations). Peach IgE sen-
sitization rates across European countries as reported from the Euro-
prevall cohort peak at 11.9% in Madrid and 13.4% in Zurich.2
Similarly, little is known about allergen(s) other than Pru p 7 poten-
tially involved in the cypress‐peach syndrome.41 Teams from southern
France and Spain reported an association of CP and PA in Pru p 3 sen-
sitized patients.42,43 Further, in a series of seven CP and PA patients,
all displayed IgE binding to a 45‐kDa CP protein, which could be out-
competed by peach extract.39 Additionally, certain allergens identified
in Japanese cedar (Cryptomeria japonica) pollen, such as Cry j 3 (thau-
matin‐like protein), CJP‐6 (isoflavone‐reductase) and CPA‐9 (subtilisin‐
like protease), show sequence identity of 40% or higher with homo-
logues in Rosaceae fruits and other plant foods, suggesting that cross‐
reactions may occur through multiple allergen families.44
TABLE 2 Pru p 7 sensitization by geographic region and peach allergy or tolerance
rPru p 7 IgE All regions Region 5 Region 4 Region 3 Region 2 Region 1
Peach allergic patients
Prevalence (number, %) 123 (62%) *** 88 (66%) ** 12 (55%) 13 (65%) *** 7 (54%) 3 (30%)
Median (IQR) (kUA/L) 3.4 (0.5‐8.3) 4.1 (0.7‐8.6) 2.8 (1.0‐10.4) 3.7 (1.1‐7.3) 0.2 (0.1‐0.6) 0.3 (0.2‐0.6)
Pru p 7 monosensitization 66/123 (54%) *** 49/88 (55%) *** 7/12 (58%) 8/13 (62%) 1/7 (14%) 1/3 (33%)
Peach tolerant patients
Prevalence (number, %) 48 (41%) *** 35 (49%) ** 4 (80%) 2 (13%) 4 (27%) 3 (27%)
Median (IQR) (kUA/L) 0.3 (0.2‐0.5) 0.3 (0.2‐0.7) 0.3 (0.2‐0.4) 0.2 (0.2; 0.2) 0.1 (0.1‐0.2) 0.2 (0.2‐0.4)
Pru p 7 monosensitization 8/48 (17%) *** 7/35 (20%) *** 0 0 0 1/3 (33%)
All patients
Prevalence (number, %) 171 (54%) 123 (60%) 16 (59%) 15 (43%) 11 (39%) 6 (29%)
Median (IQR) (kUA/L) 1.3 (0.2‐6.4) 2.3 (0.3‐6.7) 1.2 (0.5‐5.1) 3.4 (0.3‐6.3) 0.2 (0.1‐0.2) 0.2 (0.2‐0.5)
Pru p 7 monosensitization 74/171 (43%) 56/123 (46%) 7/16 (44%) 8/15 (53%) 1/11 (9%) 2/6 (33%)
Bold figures with asterisks denote statistically significant differences between PA and PT patients. Median and IQR were calculated for samples with
Pru p 7 IgE ≥0.10 kUA/L. Statistical significance flags for P‐value levels: *< 0.05; **< 0.01; ***< 0.001.
F IGURE 1 Prevalence of Pru p 7
sensitization in southern France in relation
to cypress pollen exposure levels. Cypress
pollen levels: green, low (exposure region
1); yellow, intermediate (exposure region
2); orange, high (exposure region 3); red,
very high (exposure regions 4 and 5). Birch
pollen exposure follows an inverse gradient
and is virtually absent in the southernmost
part defining the region of Marseille (5).
Pru p 7 sensitization: blue circles:
sensitized subjects; white circles: non‐
sensitized subjects. The size of each circle
indicates the number of subjects it
represents. Small black and white symbols
indicate sites of pollen counting. Cypress
pollen map reproduced with permission17
Although cypress trees are typical of Mediterranean regions,
Cupressaceae pollen dispersal also affects non‐Mediterranean envi-
ronments, including Central Europe, North America, Mexico and
Japan.41,45-48 GRP‐related allergy to Rosaceae and Citrus fruits was
reported in conjunction with Japanese cedar pollinosis.46,47,49 In
south‐central United States, mountain cedar (Juniperus ashei) pollen
is a major cause of allergic rhinoconjunctivitis.48 Pollinosis to Cupres-
saceae has been steadily increasing during the past decades, possibly
as a result of extended species distribution due to climate change
and ability of Cupressaceae pollen to travel over hundreds of
kilometres.41,44,48 Individuals with Cupressaceae pollinosis who dis-
play similar sensitization profiles due to the homology of allergens
from different Cupressaceae species 50 might become exposed to
previously unencountered, cross‐reacting foods, when changing resi-
dence regions, travelling overseas, or expanding their consumption
of fruits and vegetables as a result of healthy living trends.51 Indeed,
we found that Pru p 7 sensitization was associated with reactions to
an array of plant foods, including but not limited to Rosaceae. Mem-
bers of the GRP family are widely distributed in the plant kingdom,
share high levels of sequence identity 14,49,52 and have been
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F IGURE 2 IgE antibody levels in peach allergic and peach tolerant patients. Levels of IgE to peach and peach components, MUXF3 and
cypress pollen in peach allergic (A) and peach tolerant (B) subjects. Horizontal bars indicate median levels among positive (≥0.10 kUA/L)
observations. Dotted horizontal lines indicate the 0.10 and 0.35 kUA/L levels. Indicated above the x‐axis in each graph are the numbers of sera
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F IGURE 3 Prevalence and magnitude of Pru p 7 sensitization in relation to the severity of reactions to peach. Prevalence (A) and
concentration (B) of IgE to Pru p 7 in patients with mild, moderate or severe reactions to peach. Statistical significance flags for P‐value levels:
*< 0.05, ** <0.01, *** <0.001. In B, horizontal bars indicate median levels among positive (≥0.10 kUA/L) observations and dotted horizontal
lines mark the 0.10 and 0.35 kUA/L levels. Indicated above the x‐axis is the number of sera with IgE <0.10 kUA/L
associated with particularly severe food allergic reactions in at least
three environments: Italy,14 France 16 and Japan.49,53
In our cohort, increasing CP exposure and associated Pru p 7
sensitization was related to lower prevalence of PR‐10 sensitization
even in regions with substantial birch pollen exposure. Conversely, a
potential protective effect of birch pollen exposure has been sug-
gested with respect to LTP‐related food allergies.54 The pathophysi-
ological background of such interactions between pollen exposure
and the resulting host sensitization may bring further insight into the
geographic restriction patterns of food allergy.
In conclusion, we report here that Pru p 7 sensitization is common
in patients allergic to peach, often in the absence of sensitization to
other peach allergens. Sensitization to Pru p 7 is invariably associated
with CP sensitization and appears to be driven by CP exposure, rather
than reflecting a primary food sensitization. Biologically, Pru p 7 was
found to be extremely potent, causing basophil activation at sub‐pico-
molar concentrations. Because CP is present in continental as well as
Mediterranean environments, and given the world‐wide distribution of
related Cupressaceae species, Pru p 7 and homologous food proteins
may be an important culprit in severe allergic reactions to peach and
other plant foods in many regions of the world.
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